Biotech

All Articles

Merck ceases period 3 TIGIT test in lung cancer for futility

.Merck &amp Co.'s TIGIT program has suffered one more drawback. Months after shuttering a stage 3 mo...

After a tough year, Exscientia folds in to Recursion

.After a year defined by pipeline hairstyles, the variation of its CEO and layoffs, Exscientia will ...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapeutics was actually wowed enough with Port BioMed's bispecific invulnerable activato...

A better examine Fierce Biotech's Brutal 15

.Within this full week's incident of "The Best Pipe," our team are actually diving right into Strong...

Lilly faces period 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's event commemorating the approval of Alzheimer'...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of substantial leadership hirings, shooting...

Lykos will certainly talk to FDA to rethink its choice adhering to turndown of MDMA treatment for post-traumatic stress disorder

.Adhering to a poor presenting for Lykos Rehabs' MDMA candidate for post-traumatic stress disorder a...

AN 2 fifty percents roll call, stops stage 3 trial after records dissatisfy

.AN2 Therapies is actually rethinking its own company in response to uninspired midphase data, swear...

Merck spends $700M for bispecific, spying autoimmune position and also odds to challenge Amgen in cancer

.Merck &amp Co. is paying for $700 million in advance to challenge Amgen in a blood stream cancer ce...

Gilead pays J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences on the verge of an FDA selection for its liver health condition drug sel...